Solventum (NYSE:SOLV) Stock Moved Down to Hold by Wall Street Zen

Wall Street Zen cut shares of Solventum (NYSE:SOLV) from a buy rating to a hold rating in a report released on Saturday,Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up from $105.00) on shares of Solventum in a report on Friday. Wells Fargo & Company raised their target price on Solventum from $89.00 to $95.00 and gave the stock an “equal weight” rating in a research note on Friday. UBS Group lifted their price target on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. BTIG Research reissued a “buy” rating on shares of Solventum in a research report on Friday. Finally, Benchmark reissued a “buy” rating on shares of Solventum in a report on Thursday, October 8th. Ten investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has an average rating of “Moderate Buy” and a consensus target price of $90.27.

Solventum Trading Up 3.6%

SOLV opened at $90.34 on Friday. The firm has a market capitalization of $15.38 billion, a price-to-earnings ratio of 101.51, a price-to-earnings-growth ratio of 1.32 and a beta of 0.69. The company’s 50 day simple moving average is $87.73 and its two-hundred day simple moving average is $78.70. Solventum has a 1-year low of $62.38 and a 1-year high of $94.16. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.11. Solventum had a return on equity of 24.86% and a net margin of 1.91%. The business had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same period in the prior year, the business earned $1.50 earnings per share. The business’s revenue was down 7.0% compared to the same quarter last year. Analysts expect that Solventum will post 7.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Wellington Grp LLC increased its stake in Solventum by 50.2% during the third quarter. Wellington Grp LLC now owns 16,539 shares of the company’s stock worth $1,458,000 after acquiring an additional 5,529 shares during the last quarter. Diversified Trust Co purchased a new stake in Solventum in the third quarter valued at $214,000. Aberdeen Group plc raised its position in Solventum by 865.4% in the third quarter. Aberdeen Group plc now owns 61,369 shares of the company’s stock valued at $5,410,000 after purchasing an additional 55,012 shares during the period. Allworth Financial LP lifted its stake in shares of Solventum by 11.1% in the 3rd quarter. Allworth Financial LP now owns 5,575 shares of the company’s stock valued at $491,000 after purchasing an additional 557 shares during the last quarter. Finally, Fisher Asset Management LLC acquired a new position in shares of Solventum in the 3rd quarter valued at $239,000.

Key Headlines Impacting Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
• Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
• Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details

About Solventum

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024.

The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Solventum serves customers in the United States and international markets.